| Market Capitalization (Millions $) |
1,238,636 |
| Shares
Outstanding (Millions) |
118,757 |
| Employees |
6 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-28 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
The companyes focus is to develop therapies that target specific components of the complement system, with the goal of restoring its normal function.
Nomacopan is a dual inhibitor of C5 and LTB4, which are key components of the complement system. In preclinical studies, Nomacopan has demonstrated potent anti-inflammatory and anti-thrombotic effects, which make it a promising candidate for the treatment of various diseases. The drug has also shown a favorable safety profile in clinical trials, with no serious adverse events reported to date.
Akari is currently conducting a Phase III clinical trial of Nomacopan in PNH, which is a rare blood disorder characterized by the destruction of red blood cells. Nomacopan is being evaluated as a potential alternative to the standard of care, eculizumab, which is a monoclonal antibody that targets C If successful, Nomacopan has the potential to offer a more convenient and cost-effective treatment option for PNH patients.
In addition to PNH, Akari is also exploring the use of Nomacopan in other indications, including Guillain-Barr' syndrome, aHUS, and bullous pemphigoid. The companyes pipeline also includes a preclinical program targeting the complement pathway for the treatment of age-related macular degeneration (AMD).
Overall, Akari Therapeutics is an innovative biopharmaceutical company with a unique approach to developing therapies for rare and orphan autoimmune and inflammatory diseases. With a strong focus on the complement system and a promising lead candidate in Nomacopan, the company is well-positioned to create significant value for patients and shareholders alike.
Company Address: 401 East Jackson Street Tampa 33602 FL
Company Phone Number: 274-7510 Stock Exchange / Ticker: NASDAQ AKTX
|
